Nelson Jeffrey Edward 4/A

What Happened

• Jeffrey Edward Nelson, Chief Operating Officer of Milestone Pharmaceuticals (MIST), received a derivative award covering 204,000 shares on February 2, 2026. The filing reports an acquisition price of $0.00 and a total reported value of $0. This is an award/grant (compensation), not an open-market purchase or a sale.

Key Details

• Transaction date: February 2, 2026; Form 4 filed (amended) February 5, 2026.
• Reported price: $0.00 per share; reported total value $0 (derivative award).
• Shares owned after transaction: Not specified in this filing.
• Filing status: This is an AMENDED Form 4; footnote F1 says the exercise price on the initial filing was incorrect and has been corrected here.
• Vesting: Footnote F2—1/4 of the award vests on Feb 2, 2027, then 1/36 of the remaining shares vest each month thereafter (i.e., a four‑year vesting schedule: 1‑year cliff then monthly vesting over the next 3 years).
• No indication in this filing that shares were sold or immediately transferable.

Context

• This was a compensation award (derivative grant) subject to multi-year vesting, so the shares are not immediately owned or tradable by the insider. Such grants are common forms of executive compensation and do not by themselves indicate the insider is buying or selling stock. The amendment corrects an earlier error about the exercise price; retail investors should note the award’s vesting schedule when assessing potential future insider selling or dilution.